[Factors influencing activity of oral anticoagulants. Interactions with drugs and food].
Oral anticoagulants (OAC) are commonly used as a life-long therapy in prevention of systemic embolism in patients with atrial fibrillation, valvular heart disease and prosthetic hart valves and in the primary and secondary prevention of venous thromboembolism. They are also used for the prevention of thromboembolic events in patients with acute myocardial infarction and with angina pectoris, in patients with biological hart valves and after some types of orthopaedics surgery. The International Normalized Ratio (INR) is used to evaluate the efficacy of anti-coagulant therapy. The risk of thromboembolic and haemorrhagic complications increases when the INR is out of the therapeutic range. The aim of this study was to present information about the factors influencing activity of oral anticoagulants and interactions between oral anticoagulants and drugs or food. The effect of oral anticoagulants is influenced by genetic and environmental factors such as: medicines, food, diseases and pre-existing conditions. A common mutation in the gene coding for the cytochrome P450 (CYP2C9), with one or more combinations of its polymorphisms, is responsible for the reduced warfarin requirements or for the resistance to warfarin. A mutation in the factor IX is responsible for the risk of bleeding during OAC therapy without excessive prolongation of the prothrombin time (PT). Drugs, herbs and multivitamin supplements can alter the absorption, pharmacokinetics or pharmakodynamics of OAC. Nonsteroid anti-inflammatory drugs and paracetamol in combination with OAC seem to be the most dangerous because they are available without prescription and are used without medical consultation. Patients on OAC therapy are sensitive to changing dietary intake of vitamin K, which is supplied from phylloquinones in plants or from vitamin K-containing medicines. The effect of OAC can be influenced by other existing factors like: fever, diarrhoea, alcohol abuse or physical hyperactivity. Some malignancies or other diseases like cardiac insufficiency, hyperthyroidism and hypothyroidism or hepatic dysfunction may also affect OAC therapy. This treatment requires patients and doctors to be knowledgeable about factors influencing the activity of oral anticoagulants. For this reason educational programme on OAC therapy should be conducted among patients and doctors.
Sawicka-Powierza
Jolanta
J
Medical University of Białystok, Department of Family Medicine and Community Nursing, Poland. jolasawicka@gmail.com
Rogowska-Szadkowska
Dorota
D
Ołtarzewska
Alicja Małgorzata
AM
Chlabicz
Sławomir
S
D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage*; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics; D004347:Drug Interactions; D004351:Drug Resistance / Q000235:genetics; D018565:Food-Drug Interactions; D006470:Hemorrhage / Q000139:chemically induced; D041743:Herb-Drug Interactions; D006801:Humans; D011110:Polymorphism, Genetic; D013923:Thromboembolism / Q000517:prevention & control; D014859:Warfarin / Q000494:pharmacology
D000925:Anticoagulants; D014859:Warfarin; D003577:Cytochrome P-450 Enzyme System